AKT1 and ulcerative colitis: Lucidenic acid A emerged as the most promising compound, demonstrating exceptional binding to SRC (−9.1 kcal/mol), EGFR (−8.3 kcal/mol), and AKT1 (−8.8 kcal/mol), suggesting a multi-target therapeutic approach advantageous for treating the complex pathophysiology of ulcerative colitis.